Some HIV Patients in UK at Risk of Exhausting Treatment Options

Article

A small but growing proportion of HIV infected patients in the United Kingdom may be in danger of exhausting current treatment options, says a paper published online by the British Medical Journal (BMJ) today.

 

Highly active antiretroviral therapy (HAART) has had a dramatic impact on the health of individuals infected with HIV. But some patients experience problems while receiving HAART and may have to switch drugs on one or more occasions, raising the concern that these patients may exhaust all currently available treatment options.

 

Researchers at six large HIV centers in southeast England monitored 16,593 individuals who had attended one of the centers for care between 1996 and 2002. They found that, although patients infected with HIV are becoming increasingly exposed to different antiretroviral treatments over time, immunological and virological profiles of these patients continue to improve.

 

Currently, little evidence exists to indicate that a large proportion of patients are starting to experience therapeutic failure, say the authors. However, for a small number, treatment options are in danger of becoming exhausted. New drugs with low toxicity, which are not associated with cross resistance to existing drugs, are urgently needed for such patients, they conclude.

 

Source: British Medical Journal

Recent Videos
Lindsay K. Weir, MPH, CIC, Lead Infection Preventionist/Infection Preventionist III
•	Rebecca (Bartles) Crapanzano-Sigafoos, DrPH, MPH, CIC, FAPIC (corresponding author), executive director of APIC’s Center for Research, Practice, and Innovation, and lead author of the study.
Infection Control Today's Infection Intel: Staying Ahead With Company Updates and Product Innovations.
COVID-19 presentations at IDWeek in Las Angeles, California by Invivyd.   (Adobe Stock 333039083 by Production Perig)
Long COVID and Other Post-Viral Syndromes
Meet Jenny Hayes, MSN, RN, CIC, CAIP, CASSPT.
Infection Control Today Editorial Advisory Board: Fibi Attia, MD, MPH, CIC.
Andrea Thomas, PhD, DVM, MSc, BSc, director of epidemiology at BlueDot
mpox   (Adobe Stock 924156809 by Andreas Prott)
Meet Alexander Sundermann, DrPH, CIC, FAPIC.
Related Content